ProCE Banner Series

Next-Generation Endocrine Therapies: Opportunities in ER+/HER2- Breast Cancer Care

Join us in San Antonio or online for a CME-certified satellite symposium featuring expert perspectives on the newest generation of endocrine therapy in HR-positive/HER2-negative breast cancer. At the end of the session, experts will answer audience questions in a live question and answer session. Register now!

To Register: Please click the green “Learn More” button below. On the next page, select either “Register for In-Person Event” or “Register for Virtual Event.” Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

This symposium is sponsored by Clinical Care Options, LLC and supported by a grant from AstraZeneca. This is not an official program of the San Antonio Breast Cancer Symposium.

  AMA
Who Should Attend

This program is intended for physicians, pathologists, and other healthcare professionals who care for patients with breast cancer.

All Events

Next-Generation Endocrine Therapies: Opportunities in ER+/HER2- Breast Cancer Care

Past Events

December

07

2023

7:30 PM - 9:00 PM Central Time (CT)

In-personVirtual

San Antonio Marriott Rivercenter, 101 Bowie Street, San Antonio, Texas 78205

Topics

Registration and reception: 7:00 PM - 7:30 PM CT
  • Welcome and Introduction
  • Decoding ER+/HER2- Breast Cancer: Biology, Landscape, and Tackling Endocrine Resistance
  • Navigating Endocrine Therapy: Optimizing Treatment for ER+/HER2- MBC
  • The Rise of Oral SERDs: Reshaping the Treatment Landscape for ER+/HER2- Breast Cancer
  • SABCS 2023 Spotlight: Cutting-edge Research on Oral SERDs and SERD Similars
  • Interactive Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Breast Cancer. 

Target Audience
This program is intended for physicians, pathologists, and other healthcare professionals who care for patients with breast cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Appraise current and emerging data and guidelines to inform the use of biomarkers and genomic classifiers to assess the risk of recurrence and the role of common mutations (ESR1) in predicting response to SERDs
  • Develop treatment strategies for patients with ER+/HER2- breast cancer taking into consideration the rationale, mechanisms of action, and latest efficacy and safety data of novel oral SERDs and other ER-targeting therapies
  • Individualize the selection and sequence of systemic therapy for patients with ER-positive breast cancer, considering clinical presentation, prior treatment course, and patient comorbidities and goals
  • Formulate supportive care strategies to manage adverse events and promote oral therapy compliance using available safety and toxicity data for oral SERDs and other ER-targeting therapies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from AstraZeneca.

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191